2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T4e2,A total of 6 912 427 participants (53.6% male; mean [SD] age, 53.39 [20.13] years) consisting of 3 145 388 with COVID-19 and 3 767 039 controls with an observational period of more than 180 days were included. Alopecia areata (adjusted hazard ratio [AHR], 1.11 [95% CI, 1.07-1.15]), alopecia totalis (AHR, 1.24 [95% CI, 1.09-1.42]), vitiligo (AHR, 1.11 [95% CI, 1.04-1.19]), Behçet disease (AHR, 1.45 [95% CI, 1.20-1.74]), Crohn disease (AHR, 1.35 [95% CI, 1.14-1.60]), ulcerative colitis (AHR, 1.15 [95% CI, 1.04-1.28]), rheumatoid arthritis (AHR, 1.09 [95% CI, 1.06-1.12]), systemic lupus erythematosus (AHR, 1.14 [95% CI, 1.01-1.28]), Sjögren syndrome (AHR, 1.13 [95% CI, 1.03-1.25]), ankylosing spondylitis (AHR, 1.11 [95% CI, 1.02-1.20]), and bullous pemphigoid (AHR, 1.62 [95% CI, 1.07-2.45]) were associated with higher risk in the COVID-19 group. Subgroup analyses revealed that demographic factors, including male and female sex, age younger than 40 years, and age 40 years and older, exhibited diverse associations with the risk of autoimmune and autoinflammatory outcomes. In addition, severe COVID-19 infection requiring intensive care unit admission, the Delta period, and not being vaccinated were associated with higher risk.31:Ta4b,Few studies have investigated the association between COVID-19 and autoimmune and autoinflammatory connective tissue disorders; however, research with long-term observation remains insufficient. To investigate the long-term risk of autoimmune and autoinflammatory diseases after COVID-19 over an extended observation period. This retrospective nationwide population-based study investigated the Korea Disease Control and Prevention Agency-COVID-19-National Health Insurance Service (K-COV-N) cohort. Individuals with confirmed COVID-19 from October 8, 2020, to December 31, 2022, and controls identified among individuals who participated in the general health examination in 2018 were included in the analysis. Confirmed COVID-19. Incidence and risk of autoimmune and autoinflammatory connective tissue disorders in patients after COVID-19. Various covariates, such as demographic characteristics, general health data, socioeconomic status, and comorbidity profiles, were balanced using inverse probability weighting. A total of 6 912 427 participants (53.6% male; mean [SD] age, 53.39 [20.13] years) consisting of 3 145 388 with COVID-19 and 3 767 039 controls with an observational period of more than 180 days were included. Alopecia areata (adjusted hazard ratio [AHR], 1.11 [95% CI, 1.07-1.15]), alopecia totalis (AHR, 1.24 [95% CI, 1.09-1.42]), vitiligo (AHR, 1.11 [95% CI, 1.04-1.19]), Behçet disease (AHR, 1.45 [95% CI, 1.20-1.74]), Crohn disease (AHR, 1.35 [95% CI, 1.14-1.60]), ulcerative colitis (AHR, 1.15 [95% CI, 1.04-1.28]), rheumatoid arthritis (AHR, 1.09 [95% CI, 1.06-1.12]), systemic lupus erythematosus (AHR, 1.14 [95% CI, 1.01-1.28]), Sjögren syndrome (AHR, 1.13 [95% CI, 1.03-1.25]), ankylosing spondylitis (AHR, 1.11 [95% CI, 1.02-1.20]), and bullous pemphigoid (AHR, 1.62 [95% CI, 1.07-2.45]) were associated with higher risk in the COVID-19 group. Subgroup analyses revealed that demographic factors, including male and female sex, age younger than 40 years, and age 40 years and older, exhibited diverse associations with the risk of autoimmune and autoinflammatory outcomes. In addition, severe COVID-19 infection requiring intensive care unit admission, the Delta period, and not being vaccinated were associated with higher risk. This retrospective cohort study with an extended follow-up period found associations between COVID-19 and the long-term risk of various autoimmune and autoinflammatory connective tissue disorders. Long-term monitoring and care of patients is crucial after COVID-19, considering demographic factors, disease severity, and vaccination status, to mitigate these risks.32:Td06,ImportanceFew studies have investigated the association between COVID-19 and autoimmune and autoinflammatory connective tissue disorders; however, research with long-term observation remains insufficient.ObjectiveTo investigate the long-term risk of autoimmune and autoinflammatory diseases after COVID-19 over an extended observation period.Design, Setting, and ParticipantsThis retrospective nationwide population-based study investigated the Korea Disease Control and Prevention Agency–COVID-19–National Health Insurance Service (K-COV-N) cohort. Individuals with confirmed COVID-19 from October 8, 2020, to December 31, 2022, and controls identified among individuals who participated in the general health examination in 2018 were included in the analysis.ExposuresConfirmed COVID-19.Main Outcomes and MeasuresIncidence and risk of autoimmune and autoinflammatory connective tissue disorders in patients after COVID-19. Various covariates, such as demographic characteristics, general health data, socioeconomic status, and comorbidity profiles, were balanced using inverse probability weighting.ResultsA total of 6 912 427 participants (53.6% male; mean [SD] age, 53.39 [20.13] years) consisting of 3 145 388 with COVID-19 and 3 767 039 controls with an observational period of more than 180 days were included. Alopecia areata (adjusted hazard ratio [AHR], 1.11 [95% CI, 1.07-1.15]), alopecia totalis (AHR, 1.24 [95% CI, 1.09-1.42]), vitiligo (AHR, 1.11 [95% CI, 1.04-1.19]), Behçet disease (AHR, 1.45 [95% CI, 1.20-1.74]), Crohn disease (AHR, 1.35 [95% CI, 1.14-1.60]), ulcerative colitis (AHR, 1.15 [95% CI, 1.04-1.28]), rheumatoid arthritis (AHR, 1.09 [95% CI, 1.06-1.12]), systemic lupus erythematosus (AHR, 1.14 [95% CI, 1.01-1.28]), Sjögren syndrome (AHR, 1.13 [95% CI, 1.03-1.25]), ankylosing spondylitis (AHR, 1.11 [95% CI, 1.02-1.20]), and bullous pemphigoid (AHR, 1.62 [95% CI, 1.07-2.45]) were associated with higher risk in the COVID-19 group. Subgroup analyses revealed that demographic factors, including male and female sex, age younger than 40 years, and age 40 years and older, exhibited diverse associations with the risk of autoimmune and autoinflammatory outcomes. In addition, severe COVID-19 infection requiring intensive care unit admission, the Delta period, and not being vaccinated were associated with higher risk.Conclusions and RelevanceThis retrospective cohort study with an extended follow-up period found associations between COVID-19 and the long-term risk of various autoimmune and autoinflammatory connective tissue disorders. Long-term monitoring and care of patients is crucial after COVID-19, considering demographic factors, disease severity, and vaccination status, to mitigate these risks.33:Ta05,Alopecia areata (AA) is characterized by hair loss ranging from patches of hair loss to more extensive forms, including alopecia totalis (AT) and alopecia universalis (AU). There is a lack of consensus for treatment. Understanding current practice patterns could help the identification of treatment needs and development of standards of care. To review treatment patterns for adults with AA in the US between 2015 and 2020. This retrospective cohort study used medicine and pharmacy claims for commercially insured individuals from the IBM MarketScan Research Database to assess adults (≥18 years) newly treated for AA between October 15, 2015, and February 28, 2020. Alopecia areata was identified based on having at least 1 diagnosis of International Statistical Classification of Diseases and Related Health Problems, Tenth Revision code L63.x. Patients were required to have at least 365 days of continuous health plan enrollment before and after the cohort entry date. Patients were required to be free of AA diagnosis codes 365 days before the cohort entry date. Statistical analyses were conducted between 2019 and 2023. Main outcomes were treatment patterns for all patients with AA and subgroups of (1) patients with AT or AU and (2) those cared for by a dermatologist on the cohort entry date. Longitudinal therapy course during the first year after the diagnosis was also examined. The study cohort consisted of 45 483 individuals (mean [SD] age, 43.8 [14.2] years; 29 903 [65.7%] female). During the year of follow-up, 30 217 patients (66.4%) received at least 1 AA treatment. The most common treatments were intralesional (19 014 [41.8%]), topical (18 604 [40.9%]), intramuscular (17 328 [38.1%]), and oral (9378 [20.6%]) corticosteroids. Compared with patients without AT or AU, patients with AT or AU a lower frequency of intralesional steroid (359 [11.1%] vs 18 655 [44.1%], P < .001) and higher frequency of topical corticosteroid (817 [25.4%] vs 17 787 [42.1%], P < .001) use. Almost half of patients (21 489 [47.2%]) received no treatment on the day of diagnosis. By 12 months, 32 659 (71.8%) were not receiving any treatment, making no treatment the largest study group. In this large cohort study of commercially insured individuals, corticosteroids were the most commonly used treatment for adults with AA between 2015 and 2020. At 365 days after diagnosis, more than two-thirds of patients were no longer receiving any AA treatment. Further studies are needed to understand the reasons for the absence of treatment.34:Tcc7,ImportanceAlopecia areata (AA) is characterized by hair loss ranging from patches of hair loss to more extensive forms, including alopecia totalis (AT) and alopecia universalis (AU). There is a lack of consensus for treatment. Understanding current practice patterns could help the identification of treatment needs and development of standards of care.ObjectiveTo review treatment patterns for adults with AA in the US between 2015 and 2020.Design, Setting, and ParticipantsThis retrospective cohort study used medicine and pharmacy claims for commercially insured individuals from the IBM MarketScan Research Database to assess adults (≥18 years) newly treated for AA between October 15, 2015, and February 28, 2020. Alopecia areata was identified based on having at least 1 diagnosis of International Statistical Classification of Diseases and Related Health Problems, Tenth Revision code L63.x. Patients were required to have at least 365 days of continuous health plan enrollment before and after the cohort entry date. Patients were required to be free of AA diagnosis codes 365 days before the cohort entry date. Statistical analyses were conducted between 2019 and 2023.Main Outcomes and MeasuresMain outcomes were treatment patterns for all patients with AA and subgroups of (1) patients with AT or AU and (2) those cared for by a dermatologist on the cohort entry date. Longitudinal therapy course during the first year after the diagnosis was also examined.ResultsThe study cohort consisted of 45 483 individuals (mean [SD] age, 43.8 [14.2] years; 29 903 [65.7%] female). During the year of follow-up, 30 217 patients (66.4%) received at least 1 AA treatment. The most common treatments were intralesional (19 014 [41.8%]), topical (18 604 [40.9%]), intramuscular (17 328 [38.1%]), and oral (9378 [20.6%]) corticosteroids. Compared with patients without AT or AU, patients with AT or AU a lower frequency of intralesional steroid (359 [11.1%] vs 18 655 [44.1%], P &lt; .001) and higher frequency of topical corticosteroid (817 [25.4%] vs 17 787 [42.1%], P &lt; .001) use. Almost half of patients (21 489 [47.2%]) received no treatment on the day of diagnosis. By 12 months, 32 659 (71.8%) were not receiving any treatment, making no treatment the largest study group.Conclusions and RelevanceIn this large cohort study of commercially insured individuals, corticosteroids were the most commonly used treatment for adults with AA between 2015 and 2020. At 365 days after diagnosis, more than two-thirds of patients were no longer receiving any AA treatment. Further studies are needed to understand the reasons for the absence of treatment.25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Alopecia Totalis: condition Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Alopecia Totalis (condition). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/condition/Alopecia%20Totalis\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conditions\",\"item\":\"https://www.reachrx.ai/hub/tag/condition\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Alopecia Totalis\",\"item\":\"https://www.reachrx.ai/hub/tag/condition/Alopecia%20Totalis\"}]}}"}}]],["$","$L2f",null,{"title":"Alopecia Totalis: Research & Clinical Takeaways","description":"Discover peer-reviewed research on Alopecia Totalis with concise clinician summaries and next-step guidance.","papers":[{"doi":"10.1001/jamadermatol.2024.4233","pmid":"39504045","title":"Long-Term Risk of Autoimmune and Autoinflammatory Connective Tissue Disorders Following COVID-19","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2024-11-06T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2024.4233","source_score":529,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2024-11-09","doi":"10.1001/jamadermatol.2024.4233","days":"30","issn":"2168-6068","rank":"2","field":"Clinical Medicine","score":"529","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2024.4233","title":"Long-Term Risk of Autoimmune and Autoinflammatory Connective Tissue Disorders Following COVID-19.","journal":"JAMA dermatology","methods":"","results":"$30","abstract":"$31","keywords":[],"pubmed_id":"39504045","conclusions":"","publication_date":"2024-11-06T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2024.4233","URL":"https://doi.org/10.1001/jamadermatol.2024.4233","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2825849/jamadermatology_heo_2024_oi_240049_1734108368.45738.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"1278","type":"journal-article","issue":"12","score":1,"title":["Long-Term Risk of Autoimmune and Autoinflammatory Connective Tissue Disorders Following COVID-19"],"author":[{"given":"Yeon-Woo","family":"Heo","sequence":"first","affiliation":[{"name":"Department of Dermatology, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea"}]},{"given":"Jae Joon","family":"Jeon","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea"}]},{"given":"Min Chul","family":"Ha","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea"}]},{"given":"You Hyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea"}]},{"given":"Solam","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea"}]}],"issued":{"date-parts":[[2024,12,1]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":"160","created":{"date-time":"2024-11-06T16:00:46Z","timestamp":1730908846000,"date-parts":[[2024,11,6]]},"indexed":{"date-time":"2025-09-09T22:00:43Z","timestamp":1757455243412,"date-parts":[[2025,9,9]]},"subject":[],"abstract":"$32","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2825849"}},"subtitle":[],"deposited":{"date-time":"2024-12-18T16:01:04Z","timestamp":1734537664000,"date-parts":[[2024,12,18]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2024,12,1]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1016/S2213-2600(23)00239-4","key":"doi240049r1","year":"2023","issue":"8","author":"Parotto","volume":"11","first-page":"739","unstructured":null,"article-title":"Post-acute sequelae of COVID-19: understanding and addressing the burden of multisystem manifestations.","journal-title":"Lancet Respir Med","doi-asserted-by":"publisher"},{"DOI":"10.3233/HAB-200420","key":"doi240049r2","year":"2021","issue":"2","author":"Gebru","volume":"29","first-page":"139","unstructured":null,"article-title":"Global burden of COVID-19: situational analysis and review.","journal-title":"Hum Antibodies","doi-asserted-by":"publisher"},{"DOI":"10.1186/s12882-021-02557-x","key":"doi240049r3","year":"2021","issue":"1","author":"Jewell","volume":"22","first-page":"359","unstructured":null,"article-title":"COVID-19-related acute kidney injury: incidence, risk factors and outcomes in a large UK cohort.","journal-title":"BMC Nephrol","doi-asserted-by":"publisher"},{"DOI":"10.1055/a-1269-1405","key":"doi240049r4","year":"2022","issue":"3","author":"Müller-Wieland","volume":"130","first-page":"178","unstructured":null,"article-title":"COVID-19 and cardiovascular comorbidities.","journal-title":"Exp Clin Endocrinol Diabetes","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240049r5","year":"2021","issue":null,"author":"Yildirim","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":"Tüberk Toraks","doi-asserted-by":null},{"DOI":"10.1097/BOR.0000000000000776","key":"doi240049r6","year":"2021","issue":"2","author":"Liu","volume":"33","first-page":"155","unstructured":null,"article-title":"COVID-19 and autoimmune diseases.","journal-title":"Curr Opin Rheumatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.autrev.2020.102695","key":"doi240049r7","year":"2020","issue":"12","author":"Halpert","volume":"19","first-page":null,"unstructured":null,"article-title":"SARS-CoV-2, the autoimmune virus.","journal-title":"Autoimmun Rev","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamanetworkopen.2023.36120","key":"doi240049r8","year":"2023","issue":"10","author":"Lim","volume":"6","first-page":null,"unstructured":null,"article-title":"Autoimmune and autoinflammatory connective tissue disorders following COVID-19.","journal-title":"JAMA Netw Open","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eclinm.2023.102154","key":"doi240049r9","year":"2023","issue":null,"author":"Peng","volume":"63","first-page":null,"unstructured":null,"article-title":"Risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination: a population-based cohort study.","journal-title":"EClinicalMedicine","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240049r10","year":"2017","issue":"3","author":"Cheol Seong","volume":"46","first-page":"799","unstructured":null,"article-title":"Data resource profile: the National Health Information Database of the National Health Insurance Service in South Korea.","journal-title":"Int J Epidemiol","doi-asserted-by":null},{"DOI":"10.1093/ije/dyv319","key":"doi240049r11","year":"2017","issue":"2","author":"Lee","volume":"46","first-page":null,"unstructured":null,"article-title":"Cohort Profile: The National Health Insurance Service-National Sample Cohort (NHIS-NSC), South Korea.","journal-title":"Int J Epidemiol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2019.0629","key":"doi240049r12","year":"2019","issue":"8","author":"Lee","volume":"155","first-page":"922","unstructured":null,"article-title":"All-cause and cause-specific mortality risks associated with alopecia areata: a Korean nationwide population-based study.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.intimp.2022.109061","key":"doi240049r13","year":"2022","issue":null,"author":"Safary","volume":"110","first-page":null,"unstructured":null,"article-title":"Autoimmune inflammatory rheumatic diseases post–COVID-19 vaccination.","journal-title":"Int Immunopharmacol","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41591-022-01689-3","key":"doi240049r14","year":"2022","issue":"3","author":"Xie","volume":"28","first-page":"583","unstructured":null,"article-title":"Long-term cardiovascular outcomes of COVID-19.","journal-title":"Nat Med","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240049r15","year":"2022","issue":"8","author":null,"volume":"15","first-page":"505","unstructured":null,"article-title":"Status and characteristics of the SARS-CoV-2 variant outbreak in the Republic of Korea in January 2021.","journal-title":"Public Health Weekly Report","doi-asserted-by":null},{"DOI":"10.1016/j.hfc.2023.03.002","key":"doi240049r16","year":"2023","issue":"2S","author":"Bashir","volume":"19","first-page":"e1","unstructured":null,"article-title":"A review of heart failure in patients with COVID-19.","journal-title":"Heart Fail Clin","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240049r17","year":"2024","issue":null,"author":"Roser","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":"Front Epidemiol","doi-asserted-by":null},{"DOI":"10.3389/fimmu.2022.832394","key":"doi240049r18","year":"2022","issue":null,"author":"Hsu","volume":"13","first-page":null,"unstructured":null,"article-title":"The role of cytokines and chemokines in severe acute respiratory syndrome coronavirus 2 infections.","journal-title":"Front Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ijid.2020.09.1438","key":"doi240049r19","year":"2020","issue":null,"author":"Vassallo","volume":"101","first-page":"174","unstructured":null,"article-title":"Patients with COVID-19 exhibit different immunological profiles according to their clinical presentation.","journal-title":"Int J Infect Dis","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaut.2020.102473","key":"doi240049r20","year":"2020","issue":null,"author":"Sun","volume":"112","first-page":null,"unstructured":null,"article-title":"Characteristics and prognostic factors of disease severity in patients with COVID-19: the Beijing experience.","journal-title":"J Autoimmun","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.cyto.2020.155302","key":"doi240049r21","year":"2021","issue":null,"author":"Satis","volume":"137","first-page":null,"unstructured":null,"article-title":"Prognostic value of interleukin-18 and its association with other inflammatory markers and disease severity in COVID-19.","journal-title":"Cytokine","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240049r22","year":"2024","issue":null,"author":"Hileman","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":"Front Immunol","doi-asserted-by":null},{"DOI":"10.3390/diagnostics13040641","key":"doi240049r23","year":"2023","issue":"4","author":"Patt","volume":"13","first-page":"641","unstructured":null,"article-title":"Autoimmunity, COVID-19 Omicron variant, and olfactory dysfunction: a literature review.","journal-title":"Diagnostics (Basel)","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.antiviral.2022.105253","key":"doi240049r24","year":"2022","issue":null,"author":"Abdelnabi","volume":"198","first-page":null,"unstructured":null,"article-title":"The Omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters.","journal-title":"Antiviral Res","doi-asserted-by":"publisher"},{"DOI":"10.1186/s40001-023-01373-3","key":"doi240049r26","year":"2023","issue":"1","author":"Thiruvengadam","volume":"28","first-page":"421","unstructured":null,"article-title":"Clinical and experimental evidence suggest Omicron variant of SARS-CoV-2 is inherently less pathogenic than delta variant independent of previous immunity.","journal-title":"Eur J Med Res","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eclinm.2022.101783","key":"doi240049r27","year":"2023","issue":null,"author":"Chang","volume":"56","first-page":null,"unstructured":null,"article-title":"Risk of autoimmune diseases in patients with COVID-19: a retrospective cohort study.","journal-title":"EClinicalMedicine","doi-asserted-by":"publisher"},{"DOI":"10.1038/cmi.2017.151","key":"doi240049r28","year":"2018","issue":"6","author":"Segal","volume":"15","first-page":"586","unstructured":null,"article-title":"Vaccine-induced autoimmunity: the role of molecular mimicry and immune crossreaction.","journal-title":"Cell Mol Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1016/B978-0-444-63269-2.00054-4","key":"doi240049r29","year":null,"issue":null,"author":"Maoz-Segal","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":"Infection and Autoimmunity","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41598-019-55730-6","key":"doi240049r30","year":"2020","issue":"1","author":"Venigalla","volume":"10","first-page":"938","unstructured":null,"article-title":"A possible role for autoimmunity through molecular mimicry in alphavirus mediated arthritis.","journal-title":"Sci Rep","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.molimm.2021.06.021","key":"doi240049r31","year":"2021","issue":null,"author":"Mohkhedkar","volume":"137","first-page":"105","unstructured":null,"article-title":"Untangling COVID-19 and autoimmunity: identification of plausible targets suggests multi organ involvement.","journal-title":"Mol Immunol","doi-asserted-by":"publisher"},{"DOI":"10.3390/ijms23031716","key":"doi240049r32","year":"2022","issue":"3","author":"Gusev","volume":"23","first-page":"1716","unstructured":null,"article-title":"SARS-CoV-2–specific immune response and the pathogenesis of COVID-19.","journal-title":"Int J Mol Sci","doi-asserted-by":"publisher"},{"DOI":"10.1128/CMR.19.1.80-94.2006","key":"doi240049r33","year":"2006","issue":"1","author":"Fujinami","volume":"19","first-page":"80","unstructured":null,"article-title":"Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease.","journal-title":"Clin Microbiol Rev","doi-asserted-by":"publisher"},{"DOI":"10.3389/fimmu.2021.595150","key":"doi240049r34","year":"2021","issue":null,"author":"Hammoudeh","volume":"12","first-page":null,"unstructured":null,"article-title":"Systems immunology analysis reveals the contribution of pulmonary and extrapulmonary tissues to the immunopathogenesis of severe COVID-19 patients.","journal-title":"Front Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41577-020-00429-3","key":"doi240049r35","year":"2020","issue":"10","author":"Lee","volume":"20","first-page":"585","unstructured":null,"article-title":"The type I interferon response in COVID-19: implications for treatment.","journal-title":"Nat Rev Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ejr.2021.08.013","key":"doi240049r36","year":"2022","issue":"2","author":"Assar","volume":"44","first-page":"145","unstructured":null,"article-title":"Systemic lupus erythematosus after coronavirus disease-2019 (COVID-19) infection: case-based review.","journal-title":"Egypt Rheumatol","doi-asserted-by":"publisher"},{"DOI":"10.21037/acr-21-55","key":"doi240049r37","year":"2022","issue":null,"author":"Ramachandran","volume":"6","first-page":"14","unstructured":null,"article-title":"New onset systemic lupus erythematosus after COVID-19 infection: a case report.","journal-title":"AME Case Rep","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jdcr.2022.09.026","key":"doi240049r38","year":"2022","issue":null,"author":"Khanna","volume":"30","first-page":"30","unstructured":null,"article-title":"New diagnosis of systemic lupus erythematosus after COVID-19 vaccination: a case report and review of literature.","journal-title":"JAAD Case Rep","doi-asserted-by":"publisher"},{"DOI":"10.1136/bcr-2022-252985","key":"doi240049r39","year":"2023","issue":"5","author":"Gopalarathinam","volume":"16","first-page":null,"unstructured":null,"article-title":"Axial spondylarthritis following COVID-19 infection.","journal-title":"BMJ Case Rep","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ejr.2022.03.001","key":"doi240049r40","year":"2022","issue":"3","author":"Slouma","volume":"44","first-page":"275","unstructured":null,"article-title":"Rheumatoid arthritis occurring after coronavirus disease 2019 (COVID-19) infection: case based review.","journal-title":"Egypt Rheumatol","doi-asserted-by":"publisher"},{"DOI":"10.1080/03007995.2021.1906637","key":"doi240049r41","year":"2021","issue":"6","author":"Elemam","volume":"37","first-page":"929","unstructured":null,"article-title":"COVID-19 infection and rheumatoid arthritis: mutual outburst cytokines and remedies.","journal-title":"Curr Med Res Opin","doi-asserted-by":"publisher"},{"DOI":"10.1097/MD.0000000000033821","key":"doi240049r42","year":"2023","issue":"20","author":"Zhao","volume":"102","first-page":null,"unstructured":null,"article-title":"Analysis of the potential relationship between COVID-19 and Behcet’s disease using transcriptome data.","journal-title":"Medicine (Baltimore)","doi-asserted-by":"publisher"},{"DOI":"10.1007/s10067-020-05073-9","key":"doi240049r44","year":"2020","issue":"7","author":"Misra","volume":"39","first-page":"2055","unstructured":null,"article-title":"Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets.","journal-title":"Clin Rheumatol","doi-asserted-by":"publisher"},{"DOI":"10.1002/ski2.86","key":"doi240049r45","year":"2022","issue":"1","author":"Herzum","volume":"2","first-page":null,"unstructured":null,"article-title":"New-onset vitiligo following COVID-19 disease.","journal-title":"Skin Health Dis","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jdcr.2022.01.030","key":"doi240049r46","year":"2022","issue":null,"author":"Schmidt","volume":"22","first-page":"47","unstructured":null,"article-title":"Vitiligo following COVID-19: a case report and review of pathophysiology.","journal-title":"JAAD Case Rep","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.det.2016.11.014","key":"doi240049r47","year":"2017","issue":"2","author":"Rashighi","volume":"35","first-page":"257","unstructured":null,"article-title":"Vitiligo pathogenesis and emerging treatments.","journal-title":"Dermatol Clin","doi-asserted-by":"publisher"},{"DOI":"10.23880/VIJ-16000181","key":"doi240049r48","year":"2018","issue":null,"author":"Dwivedi","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":"Virol Immunol J","doi-asserted-by":"publisher"},{"DOI":"10.1134/S0006297920120068","key":"doi240049r49","year":"2020","issue":"12","author":"Chernyak","volume":"85","first-page":"1543","unstructured":null,"article-title":"COVID-19 and oxidative stress.","journal-title":"Biochemistry (Mosc)","doi-asserted-by":"publisher"},{"DOI":"10.1155/2021/5575111","key":"doi240049r50","year":"2021","issue":null,"author":"Olson","volume":"2021","first-page":null,"unstructured":null,"article-title":"New-onset bullous pemphigoid in a COVID-19 patient.","journal-title":"Case Rep Dermatol Med","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaci.2016.08.012","key":"doi240049r51","year":"2017","issue":"3","author":"Riani","volume":"139","first-page":"863","unstructured":null,"article-title":"Bullous pemphigoid outcome is associated with CXCL10-induced matrix metalloproteinase 9 secretion from monocytes and neutrophils but not lymphocytes.","journal-title":"J Allergy Clin Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1186/s12887-017-0813-0","key":"doi240049r52","year":"2017","issue":"1","author":"Baroero","volume":"17","first-page":"60","unstructured":null,"article-title":"Three case reports of post immunization and post viral Bullous Pemphigoid: looking for the right trigger.","journal-title":"BMC Pediatr","doi-asserted-by":"publisher"},{"DOI":"10.21203/rs.3.rs-1211792/v1","key":"doi240049r25","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Diamond? M, Halfmann? P, Maemura? T, . The SARS-CoV-2 B.1.1.529 Omicron virus causes attenuated infection and disease in mice and hamsters.? Res Sq. Preprint posted online December 29, 2021. doi:10.21203/rs.3.rs-1211792/v1?","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":"10.1101/2022.10.20.22281265","key":"doi240049r43","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Shen? Y, Voigt? A, Goranova? L, . Evidence of a Sjögren’s disease–like phenotype following COVID-19.? medRxiv. 2022; doi:10.1101/2022.10.20.22281265","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"}],"short-title":[],"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12,1]]}},"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"published-print":{"date-parts":[[2024,12,1]]},"reference-count":52,"published-online":null,"references-count":52,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":10},"unpaywall":{"doi":"10.1001/jamadermatol.2024.4233","is_oa":false,"title":"Long-Term Risk of Autoimmune and Autoinflammatory Connective Tissue Disorders Following COVID-19","updated":"2025-05-22T18:42:22+00:00","published_date":"2024-11-06","best_oa_location":null}},"created_at":"2025-09-20T05:48:19.207Z","updated_at":"2025-09-20T06:24:36.980Z","tags":[{"paper_doi":"10.1001/jamadermatol.2024.4233","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4233","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4233","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4233","tag_type":"condition","value":"Alopecia Areata","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4233","tag_type":"condition","value":"Alopecia Totalis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4233","tag_type":"condition","value":"Ankylosing Spondylitis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4233","tag_type":"condition","value":"Behcet Disease","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4233","tag_type":"condition","value":"Bullous Pemphigoid","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4233","tag_type":"condition","value":"COVID-19","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4233","tag_type":"condition","value":"Crohn Disease","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4233","tag_type":"condition","value":"Rheumatoid Arthritis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4233","tag_type":"condition","value":"Sjogren Syndrome","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4233","tag_type":"condition","value":"Systemic Lupus Erythematosus","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4233","tag_type":"condition","value":"Ulcerative Colitis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4233","tag_type":"condition","value":"Vitiligo","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4233","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4233","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4233","tag_type":"sample_size","value":"n=6912427","value_numeric":6912427},{"paper_doi":"10.1001/jamadermatol.2024.4233","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4233","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4233","tag_type":"warning","value":"Absolute event counts and incidence rates were not provided in the excerpt.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4233","tag_type":"warning","value":"Associations are reported; causality cannot be inferred from this observational design.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.4233","tag_type":"warning","value":"Subgroup findings (sex, age, severity, variant period, vaccination) were noted without numeric effect sizes.","value_numeric":null}],"summaries":{"practice_takeaway":"Monitor for autoimmune and autoinflammatory connective tissue disorders after COVID-19, with extra vigilance after severe infection, during Delta-period infections, and in unvaccinated patients. Consider sex and age when assessing risk, as associations varied across these groups.","what_studied":"A retrospective nationwide cohort from Korea (K-COV-N) compared people with confirmed COVID-19 (October 8, 2020–December 31, 2022) to controls from 2018 health examinations to assess long-term (>180 days) risk of autoimmune and autoinflammatory connective tissue disorders using inverse probability weighting.","key_result":"Among 6,912,427 participants (3,145,388 COVID-19; 3,767,039 controls), COVID-19 was associated with higher adjusted hazard for several outcomes: alopecia areata 1.11 (95% CI, 1.07-1.15), alopecia totalis 1.24 (1.09-1.42), vitiligo 1.11 (1.04-1.19), Behcet disease 1.45 (1.20-1.74), Crohn disease 1.35 (1.14-1.60), ulcerative colitis 1.15 (1.04-1.28), rheumatoid arthritis 1.09 (1.06-1.12), systemic lupus erythematosus 1.14 (1.01-1.28), Sjogren syndrome 1.13 (1.03-1.25), ankylosing spondylitis 1.11 (1.02-1.20), and bullous pemphigoid 1.62 (1.07-2.45); risks were higher with ICU-level severity, during the Delta period, and without vaccination (no effect sizes provided)."}},{"doi":"10.1001/jamadermatol.2023.3109","pmid":"37728940","title":"Treatment Patterns for Alopecia Areata in the US","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2023-09-20T00:00:00.000Z","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/10512165","source_score":101,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2023-11-20","doi":"10.1001/jamadermatol.2023.3109","days":"30","issn":"2168-6068","rank":"5","field":"Clinical Medicine","score":"101","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2023.3109","title":"Treatment Patterns for Alopecia Areata in the US.","journal":"JAMA dermatology","methods":"","results":"The study cohort consisted of 45 483 individuals (mean [SD] age, 43.8 [14.2] years; 29 903 [65.7%] female). During the year of follow-up, 30 217 patients (66.4%) received at least 1 AA treatment. The most common treatments were intralesional (19 014 [41.8%]), topical (18 604 [40.9%]), intramuscular (17 328 [38.1%]), and oral (9378 [20.6%]) corticosteroids. Compared with patients without AT or AU, patients with AT or AU a lower frequency of intralesional steroid (359 [11.1%] vs 18 655 [44.1%], P < .001) and higher frequency of topical corticosteroid (817 [25.4%] vs 17 787 [42.1%], P < .001) use. Almost half of patients (21 489 [47.2%]) received no treatment on the day of diagnosis. By 12 months, 32 659 (71.8%) were not receiving any treatment, making no treatment the largest study group.","abstract":"$33","keywords":[],"pubmed_id":"37728940","conclusions":"","publication_date":"2023-09-20T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2023.3109","URL":"https://doi.org/10.1001/jamadermatol.2023.3109","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2809354/jamadermatology_lee_2023_br_230016_1699989235.00151.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"1253","type":"journal-article","issue":"11","score":1,"title":["Treatment Patterns for Alopecia Areata in the US"],"author":[{"given":"Hemin","family":"Lee","sequence":"first","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts"},{"name":"Departments of Medicine and Dermatology, University of Minnesota, Minneapolis"}]},{"given":"Kathie P.","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}]},{"given":"Arash","family":"Mostaghimi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}]},{"given":"Niteesh K.","family":"Choudhry","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}]}],"issued":{"date-parts":[[2023,11,1]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":"159","created":{"date-time":"2023-09-20T15:12:06Z","timestamp":1695222726000,"date-parts":[[2023,9,20]]},"indexed":{"date-time":"2025-05-31T11:22:11Z","timestamp":1748690531364,"date-parts":[[2025,5,31]]},"subject":[],"abstract":"$34","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2809354"}},"subtitle":[],"deposited":{"date-time":"2023-11-15T16:02:50Z","timestamp":1700064170000,"date-parts":[[2023,11,15]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2023,11,1]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1038/jid.2013.464","key":"dbr230016r1","year":"2014","issue":"4","author":"Mirzoyev","volume":"134","first-page":"1141","unstructured":null,"article-title":"Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990-2009.","journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.23736/S0392-0488.19.06458-7","key":"dbr230016r2","year":"2019","issue":"6","author":"Rossi","volume":"154","first-page":"609","unstructured":null,"article-title":"Italian Guidelines in diagnosis and treatment of alopecia areata.","journal-title":"G Ital Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1111/ajd.2019.60.issue-2","key":"dbr230016r3","year":"2019","issue":"2","author":"Cranwell","volume":"60","first-page":"163","unstructured":null,"article-title":"Treatment of alopecia areata: an Australian expert consensus statement.","journal-title":"Australas J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2020.03.004","key":"dbr230016r4","year":"2020","issue":"1","author":"Meah","volume":"83","first-page":"123","unstructured":null,"article-title":"The Alopecia Areata Consensus of Experts (ACE) study: results of an international expert opinion on treatments for alopecia areata.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"dbr230016r5","year":"2015","issue":"9","author":"Farhangian","volume":"14","first-page":"1012","unstructured":null,"article-title":"Treatment of alopecia areata in the United States: a retrospective cross-sectional study.","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.4103/ijt.ijt_53_17","key":"dbr230016r6","year":"2017","issue":"4","author":"Hussain","volume":"9","first-page":"160","unstructured":null,"article-title":"Utilization of mental health resources and complementary and alternative therapies for alopecia areata: a U.S. survey.","journal-title":"Int J Trichology","doi-asserted-by":"publisher"},{"DOI":"10.1007/s12325-021-01845-0","key":"dbr230016r7","year":"2021","issue":"9","author":"Senna","volume":"38","first-page":"4646","unstructured":null,"article-title":"Alopecia areata treatment patterns, healthcare resource utilization, and comorbidities in the US population using insurance claims.","journal-title":"Adv Ther","doi-asserted-by":"publisher"},{"DOI":"10.1111/jde.2017.44.issue-11","key":"dbr230016r8","year":"2017","issue":"11","author":"Lee","volume":"44","first-page":"1199","unstructured":null,"article-title":"Management of alopecia areata: updates and algorithmic approach.","journal-title":"J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.18553/jmcp.2022.28.4.426","key":"dbr230016r9","year":"2022","issue":"4","author":"Mostaghimi","volume":"28","first-page":"426","unstructured":null,"article-title":"All-cause health care resource utilization and costs among adults with alopecia areata: a retrospective claims database study in the United States.","journal-title":"J Manag Care Spec Pharm","doi-asserted-by":"publisher"},{"DOI":"10.4103/ijt.ijt_67_20","key":"dbr230016r11","year":"2020","issue":"5","author":"Lavian","volume":"12","first-page":"234","unstructured":null,"article-title":"Validation of case identification for alopecia areata using international classification of diseases coding.","journal-title":"Int J Trichology","doi-asserted-by":"publisher"},{"DOI":null,"key":"dbr230016r12","year":"2008","issue":"12","author":"Faraone","volume":"33","first-page":"700","unstructured":null,"article-title":"Interpreting estimates of treatment effects: implications for managed care.","journal-title":"P T","doi-asserted-by":null},{"DOI":"10.1002/cpt.v99.3","key":"dbr230016r13","year":"2016","issue":"3","author":"Wang","volume":"99","first-page":"325","unstructured":null,"article-title":"Transparency and reproducibility of observational cohort studies using large healthcare databases.","journal-title":"Clin Pharmacol Ther","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2023.0002","key":"dbr230016r14","year":"2023","issue":"4","author":"Mostaghimi","volume":"159","first-page":"411","unstructured":null,"article-title":"Trends in prevalence and incidence of alopecia areata, alopecia totalis, and alopecia universalis among adults and children in a US employer-sponsored insured population.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"dbr230016r10","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Hansen? L. IBM MarketScan Research Databases for life sciences researchers. Accessed August 5, 2022. https://www.ibm.com/downloads/cas/0NKLE57Y","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11,1]]}},"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"published-print":{"date-parts":[[2023,11,1]]},"reference-count":14,"published-online":null,"references-count":14,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":5},"unpaywall":{"doi":"10.1001/jamadermatol.2023.3109","is_oa":true,"title":"Treatment Patterns for Alopecia Areata in the US","updated":"2025-07-30T00:59:52+00:00","published_date":"2023-09-20","best_oa_location":{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/10512165","pmh_id":"oai:pubmedcentral.nih.gov:10512165","url_for_pdf":null,"url_for_landing_page":"https://www.ncbi.nlm.nih.gov/pmc/articles/10512165"}}},"created_at":"2025-09-20T18:05:35.957Z","updated_at":"2025-09-20T18:19:17.906Z","tags":[{"paper_doi":"10.1001/jamadermatol.2023.3109","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.3109","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.3109","tag_type":"condition","value":"Alopecia Areata","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.3109","tag_type":"condition","value":"Alopecia Totalis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.3109","tag_type":"condition","value":"Alopecia Universalis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.3109","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.3109","tag_type":"sample_size","value":"n=45,483","value_numeric":45483},{"paper_doi":"10.1001/jamadermatol.2023.3109","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.3109","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.3109","tag_type":"warning","value":"Assigned days‑of‑supply rules in the supplement may influence duration estimates; full text may provide additional context.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.3109","tag_type":"warning","value":"Results are limited to commercially insured adults in claims; details for the dermatologist‑managed subgroup and non‑steroid therapies are not provided in the excerpt.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.3109","tag_type":"warning","value":"The text states higher topical corticosteroid use in AT/AU but reports 25.4% vs 42.1%, which implies lower; interpret directionality with caution.","value_numeric":null}],"summaries":{"limitations":"Findings reflect commercially insured adults using claims data, and reasons for the absence of treatment were not assessed.","what_studied":"A retrospective cohort of commercially insured US adults (≥18 years) with new alopecia areata from 2015–2020 in IBM MarketScan claims, examining first‑year treatment patterns overall and in subgroups with alopecia totalis/universalis and those seen by dermatology at diagnosis.","key_result":"Among 45,483 adults, 30,217 (66.4%) received ≥1 AA treatment in 12 months; most used intralesional (19,014; 41.8%), topical (18,604; 40.9%), intramuscular (17,328; 38.1%), or oral (9,378; 20.6%) corticosteroids. On diagnosis day, 21,489 (47.2%) had no treatment; by 12 months, 32,659 (71.8%) were not receiving any treatment; in AT/AU vs non‑AT/AU, intralesional steroid use was 11.1% (359) vs 44.1% (18,655) and topical steroid use was 25.4% (817) vs 42.1% (17,787).","practice_takeaway":"Corticosteroids were the mainstay for AA in routine US care, yet most adults had no ongoing therapy by 12 months; plan early follow‑up and reassess treatment needs over the first year."}}],"initialOffset":2,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"condition","value":"Alopecia Totalis"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Conditions","href":"/hub/tag/condition"},{"name":"Alopecia Totalis"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"condition","hub_tag_value":"Alopecia Totalis"}}}]]

Papers